Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA Therapeutics Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. announced they have formed a new agreement, extending their existing strategic partnership – formed originally in 2004 – to lead the development and commercialization of RNA therapeutics. [Alnylam Pharmaceuticals, Inc.] Press Release Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies Incyte Corporation and Agenus Inc. announced a global license, development and commercialization agreement focused on novel immuno-therapeutics using Agenus’ proprietary Retrocyte Displayâ„¢ antibody discovery platform. [Incyte Corporation] Press Release Argos Therapeutics and Saint-Gobain Announce Agreement for Production of Disposables Used in Automated Manufacturing of Fully Personalized Immunotherapies Argos Therapeutics Inc. announced a collaboration with Saint-Gobain’s Performance Plastics division. Saint-Gobain will partner with Argos to design, integrate and scale production of a range of disposables for use in the automated manufacturing of Argos’ lead product candidate, AGS-003, currently being tested in a Phase III clinical trial for the treatment of metastatic renal cell carcinoma. [Argos Therapeutics Inc.] Press Release Intellia Therapeutics, Novartis Form Partnership to Develop New Cell Therapies Using CRISPR/Cas9 Technology Intellia Therapeutics announced a five-year research and development collaboration with Novartis to accelerate the ex vivo development of new CRISPR/Cas9-based therapies using chimeric antigen receptor T cells and hematopoietic stem cells. [Intellia Therapeutics] Press Release MedImmune Enters Licensing Agreement with Omnis Pharmaceuticals for Oncolytic Viruses in Immuno-Oncology AstraZeneca announced that MedImmune has entered into a licensing agreement with Omnis Pharmaceuticals. This agreement will allow MedImmune to combine key agents from its investigational immunotherapy portfolio with Omnis’ lead investigational oncolytic virus program, a genetically engineered strain of vesicular stomatitis virus. [AstraZeneca] Press Release Cardio3 BioSciences Enters Immuno-Oncology Space with Acquisition of OnCyte CAR T-Cell Portfolio from Celdara Medical Cardio3 BioSciences announced the acquisition of OnCyte, the oncology division of privately-held U.S. biotechnology company Celdara Medical, and its portfolio of immuno-oncology product candidates. [Cardio3 BioSciences] Press Release Aratana Therapeutics Granted Full License for AT-004 by USDA Aratana Therapeutics, Inc. announced that AT-004, the company’s canine-specific monoclonal antibody targeting CD20 as an aid in the treatment of B-cell lymphoma in dogs, has received a full license from the U.S. Department of Agriculture (USDA). [Aratana Therapeutics, Inc.] Press Release Argos Therapeutics Provides Update on Clinical Research for Investigational Fully Personalized Immunotherapy for the Treatment of HIV Argos Therapeutics Inc. provided an update on its clinical research program for AGS-004, the company’s investigational fully personalized immunotherapy for the treatment of HIV. The primary endpoint of the trial was not achieved. [Argos Therapeutics Inc.] Press Release OncoSec Medical Plans to Initiate Pilot Study in Triple Negative Breast Cancer OncoSec Medical Inc., a company developing DNA-based intratumoral cancer immunotherapies plans to initiate a pilot study to assess IL-12 ImmunoPulse in patients with triple negative breast cancer. [OncoSec Medical Inc.] Press Release |